| 000 | 01950nam a2200433 4500 | ||
|---|---|---|---|
| 001 | 7701 | ||
| 010 | _a9291681687 | ||
| 090 | _a7701 | ||
| 100 | _a20050111d2004 y0pory50 ba | ||
| 101 | _aeng | ||
| 200 |
_aHepatitis C and injecting drug use _eimpact, costs and policy options _fEuropean Monitoring Centre for Drugs and Drug Addiction _ged. lit. Johannes Jager, Wien Limburg ... [et all.] |
||
| 210 |
_aLuxembourg _cOffice for Official Publications of the European Communities _d2004 |
||
| 215 |
_a389 p. _d24 cm |
||
| 225 |
_aEMCDDA - Scientific Monograph Series _v7 |
||
| 330 | _aPart I - Natural history, treatment, quality of life, epidemiology and prevention. Part II - Models of hepatitis C, injecting drug use and policy options. Part III - Healthcare costs of drug-related hepatitis C infection. Part IV - Wider costs of drug use. Part V - Cost-effectiveness of needle and syringe programmes and methadone maintenance. | ||
| 606 |
_aSAÚDE PÚBLICA _91370 |
||
| 606 |
_aTRATAMENTO DE TOXICODEPENDENTE _9104400 |
||
| 606 |
_aMETADONA _9102402 |
||
| 606 |
_aCONSUMO DE DROGA _95102 |
||
| 606 |
_aPREVENÇÃO PRIMÁRIA _95157 |
||
| 606 |
_aPOLÍTICA SOCIAL _91220 |
||
| 606 |
_aHEPATITE _9104401 |
||
| 606 |
_aHIV _9945 |
||
| 606 |
_aPROGRAMAS DE TRATAMENTO _98719 |
||
| 606 |
_aUNIÃO EUROPEIA _9100 |
||
| 700 |
_aJager _bJager _4340 _98720 |
||
| 701 |
_aLimburg _bWien _4340 _9104402 |
||
| 701 |
_aKretzschmar _bMirjam _4340 _9104403 |
||
| 701 |
_aPostma _bMaarten _4340 _9104404 |
||
| 701 |
_aWiessing _bLucas _4340 _9104405 |
||
| 710 |
_aEUROPEAN MONITORING CENTER FOR DRUGS AND DRUG ADDICTION - EMCDDA _98685 |
||
| 852 | _jDRO227 | ||